Managing Myeloma: Where We Are, Where We’re Going, and Where We SHOULD Be Going (Time to Choose Sides!)


Live Webinar Registration

Join us on Friday, December 4, 2020, for a virtual CME-certified Friday Satellite Symposium preceding the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

Friday, December 4, 2020
8:00 AM – 10:00 AM PT  Scientific Program

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma (MM).

Program Overview

In the last 17 years, clinicians and patients have witnessed significant advances in MM management, with the development of new strategies for establishing diagnosis, assessing prognosis, monitoring minimal residual disease (MRD), and delivering supportive care. Even more remarkably, in this time 14 new drugs have been approved by the US Food and Drug Administration for use in MM.

This expansion of MM management options brings both opportunities and challenges for oncology health care providers (HCPs). Furthermore, the rapidity with which clinical data relating to MM therapy continues to evolve all but ensures that the MM treatment paradigm will continue to change significantly in the near future.

This virtual symposium will help hematologist-oncologists weigh the current clinical evidence regarding the development of personalized treatment strategies for patients with newly diagnosed and relapsed MM. Additionally, the presentations in this activity will provide evidence supporting the emerging MM management strategies that are likely to soon become standard practice.

This symposium will follow a debate format and feature audience polling relating to the proffered arguments, as well as panel discussions.

Learning Objectives

At the conclusion of this activity, participants should be better able to:
  • Evaluate emerging data regarding the approach to maintenance therapy based on MRD status
  • Describe the options available to patients who have relapsed from or are resistant to multiple prior therapies
  • Incorporate the use of novel agent/monoclonal antibody–based regimens for newly diagnosed or relapsed/refractory MM patients based on currently available evidence


Hearn Jay Cho, MD, PhD—Program Co-Chair
Icahn School of Medicine at Mount Sinai
New York, New York
Multiple Myeloma Research Foundation
Norwalk, Connecticut

Paul G. Richardson, MD—Program Co-Chair
Dana-Farber Cancer Institute
Boston, Massachusetts

A. Keith Stewart, MBChB—Program Co-Chair
University of Toronto
Princess Margaret Cancer Centre
University Health Network
Toronto, Ontario, Canada

Adam D. Cohen, MD
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Suzanne Lentzsch, MD, PhD
Columbia University Medical Center
New York, New York

David S. Siegel, MD, PhD
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey


8:00 AM
Introduction and Overview
Hearn Jay Cho, MD, PhD; Paul G. Richardson, MD; and A. Keith Stewart, MBChB—Program Co-Chairs
8:10 AM
Debate 1: Would You Rather Treat with a 3- or 4-Drug Induction Regimen?
• 3-Drug Regimens
  Hearn Jay Cho, MD, PhD
• 4-Drug Regimens
  Paul G. Richardson, MD
8:45 AM
Debate 2: Would You Rather Continue Indefinitely or Stop at MRD Negativity?
• Continuous Maintenance
   A. Keith Stewart, MBChB
• Stop Maintenance After MRD Negativity Achieved
  Suzanne Lentzsch, MD, PhD
9:20 AM
Debate 3: Would You Rather Use Immune-Based Therapies Earlier or Exhaust All Other Options First?
• Immune-Based Therapies
  Adam D. Cohen, MD
• Exhaust All Other Options First
  David S. Siegel, MD, PhD
9:50 AM
Questions and Answers and Concluding Remarks

Join the discussion on twitter: #RMELiveMM

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Prior to the live webcast, you will receive an email from RedMedEd containing instructions on where and how to log in.

Jointly provided by

Support for this activity has been provided through educational grants from Adaptive Biotechnologies Corporation; Amgen Inc.; Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc., and Oncopeptides.